Green light for Celgene’s targeted AML drug
admin 2nd August 2017 Uncategorised 0US regulators have issued a green light for Celgene and Agios’ Idhifa, the first and only targeted treatment for adult patients with relapsed/refractory acute myeloid leukaemia and an isocitrate dehydrogenase-2 mutation.
More: Green light for Celgene’s targeted AML drug
Source: News